Toxicogenomics: Integrating Genomic Data into Preclinical Safety Assessment
Toxicogenomics combines toxicology with genomics to study how gene expression changes in response to chemical exposures. By profiling global transcriptional changes following treatment with investigational compounds, toxicogenomics offers insight into the molecular mechanisms underlying toxicity. This approach enhances early risk assessment by identifying biomarkers and adverse outcome pathways before overt toxic effects are observed.
In preclinical models, RNA is extracted from target tissues at various time points post-dosing and analyzed using platforms such as RNA sequencing or microarrays. Gene expression signatures can reveal pathways involved in oxidative stress, mitochondrial dysfunction, DNA damage, apoptosis, or inflammation. These data are valuable in distinguishing between adaptive and adverse responses and provide mechanistic context for histopathology findings or clinical chemistry changes.
Toxicogenomic profiling is particularly useful when assessing compounds with novel mechanisms of action or limited historical toxicology data. It enables identification of off-target effects and supports the refinement of dosing regimens to mitigate toxic responses. Additionally, the approach aids in species comparison, helping determine whether observed transcriptomic responses are likely to translate to humans.
Regulatory interest in toxicogenomics continues to grow, with agencies recognizing its potential in predictive toxicology, classification of compounds, and biomarker qualification. Initiatives such as the FDA’s Predictive Toxicology Roadmap and the use of the TG-GATES database exemplify this trend.
By incorporating toxicogenomic data into standard preclinical workflows, researchers can improve mechanistic understanding of toxic effects, prioritize candidate compounds for further development, and support regulatory submissions with evidence-based safety evaluations.